SCHEMBL23903180

SCHEMBL23903180

CNCC1CC(NC)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18543785 1.00
SCHEMBL18543787 1.00
SCHEMBL18543781 0.87
SCHEMBL18543793 0.87
SCHEMBL17919941 0.81 L3MBTL1 (0.33)
SCHEMBL13793409 0.81 L3MBTL1 (0.33)
SCHEMBL16224995 0.81 L3MBTL1 (0.33)
SCHEMBL19418920 0.79 SIGMAR1 (0.35)
SCHEMBL5684791 0.79 SIGMAR1 (0.35)
SCHEMBL12599088 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3733663-B1 1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER CHENGDU JINRUI FOUND BIOTECH CO LTD (CN) 2023-05-17 EP disclosed
WO-2021197250-A1 NOVEL COMPOUND AS REARRANGED DURING TRANSFECTION KINASE INHIBITOR 南京天印健华医药科技有限公司 2021-10-07 WO disclosed